medigraphic.com
ISSN 0016-3813 (Impreso)

2014, Número s3

<< Anterior Siguiente >>

Gac Med Mex 2014; 150 (s3)


Glaucoma: corrientes en estudio sobre su etiología

Serna-Ojeda JC, Flores-Reyes EM, Hartleben-Matkin C

Idioma: Español
Referencias bibliográficas: 50
Paginas: 317-323
Archivo PDF: 252.51 Kb.


RESUMEN

Antecedentes: Existen diferentes etiologías relacionadas con el glaucoma, con la participación de distintos sistemas en el origen y desarrollo de la enfermedad. Métodos: Se realiza una revisión de la literatura. Resultados: La información es dividida en cinco temas principales: enfermedad sistémica, enfermedad neurodegenerativa, enfermedad genética, enfermedad inmunológica y envejecimiento de la malla trabecular. Se mencionan importantes hallazgos, antiguos y recientes, de cada nivel que permiten establecer una relación con el glaucoma, así como enumerar algunas de las vías de investigación actuales. Conclusión: El glaucoma es una enfermedad multifactorial que presenta una interacción compleja de eventos a distintos niveles del organismo. El estudio de su etiología debe orientar hacia la búsqueda de nuevas terapias.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002;86(2):238-42.

  2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-7.

  3. Antón A, Andrada MT, Mujica V, Calle MA, Portela J, Mayo A. Prevalence of primary open-angle glaucoma in a Spanish population: the Segovia study. J Glaucoma. 2004;13(5):371-6.

  4. Foster PJ, Johnson GJ. Glaucoma in China: how big is the problem? Br J Ophthalmol. 2001;85(11):1277-82.

  5. Buhrmann RR, Quigley HA, Barron Y, West SK, Oliva MS, Mmbaga BB. Prevalence of glaucoma in a rural East African population. Invest Ophthalmol Vis Sci. 2000;41(1):40-8.

  6. Cook C, Foster P. Epidemiology of glaucoma: what’s new? Can J Ophthalmol. 2012;47(3):223-6.

  7. Pache M, Flammer J. A sick eye in a sick body? Systemic findings in patients with primary open-angle glaucoma. Surv Ophthalmol. 2006; 51(3):179-212.

  8. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 2000;107(7):1287-93.

  9. Wilson MR, Hertzmark E, Walker AM, Childs-Shaw K, Epstein DL. A case-control study of risk factors in open angle glaucoma. Arch Ophthalmol. 1987;105(8):1066-71.

  10. Graham SL, Drance SM. Nocturnal hypotension: role in glaucoma progression. Surv Ophthalmol. 1999;43 Suppl 1:S10-6.

  11. Graham SL, Drance SM, Wijsman K, Douglas GR, Mikelberg FS. Ambulatory blood pressure monitoring in glaucoma. The nocturnal dip. Ophthalmology. 1995;102(1):61-9.

  12. Flammer J, Konieczka K, Flammer AJ. The primary vascular dysregulation syndrome: implications for eye diseases. EPMA J. 2013;4(1):14. [Internet] Disponible en: http://www.epmajournal.com/content/4/1/14.

  13. Leske MC, Wu SY, Nemesure B, Hennis A. Incident open-angle glaucoma and blood pressure. Arch Ophthalmol. 2002;120(7):954-9.

  14. Flammer J, Konieczka K, Bruno RM, Virdis A, Flammer AJ, Taddei S. The eye and the heart. Eur Heart J. 2013;34(17):1270-8.

  15. Broadway DC, Drance SM. Glaucoma and vasospasm. Br J Ophthalmol. 1998;82(8):862-70.

  16. Caprioli J, Coleman AL. Blood pressure, perfusion pressure, and glaucoma. Am J Ophthalmol. 2010;149(5):704-12.

  17. Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy? Surv Ophthalmol. 2007;52 Suppl 2:S162-73.

  18. Emre M, Orgϋl S, Haufschild T, Shaw S, Flammer J. Increased plasma endothelin- 1 level in patients with progressive open angle glaucoma. Br J Ophthalmol. 2005;89(1):60-3.

  19. Mojon DS, Hess CW, Goldblum D, et al. High prevalence of glaucoma in patients with sleep apnea syndrome. Ophthalmology. 1999;106(5):1009-12.

  20. Onen SH, Mouriaux F, Berramdane L, Dascotte JC, Kulik JF, Rouland JF. High prevalence of sleep-disordered breathing in patients with primary open-angle glaucoma. Acta Ophthalmol Scand. 2000;78(6):638-41.

  21. Lin CC, Hu CC, Ho JD, Chiu HW, Lin HC. Obstructive sleep apnea and increased risk of glaucoma: a population-based matched-cohort study. Ophthalmology. 2013;120(8):1559-64.

  22. Erb C, Thiel HJ, Flammer J. The psychology of the glaucoma patient. Curr Opin Ophthalmol. 1998;9(2):65-70.

  23. Gupta N, Yücel YH. Brain changes in glaucoma. Eur J Ophthalmol. 2003;13 Suppl 3:S32-5.

  24. Wein FB, Levin LA. Current understanding of neuroprotection in glaucoma. Curr Opin Ophthalmol. 2002;13(2):61-7.

  25. Ritch R. Neuroprotection: is it already applicable to glaucoma therapy? Curr Opin Ophthalmol. 2000;11(2):78-84.

  26. Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer’s disease. Eur Neurol. 2002;47(3):165-8.

  27. Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma, II: the site of injury and susceptibility to damage. Arch Ophthalmol. 1981;99(4):635-49.

  28. McKinnon SJ. Glaucoma, apoptosis, and neuroprotection. Curr Opin Ophthalmol. 1997;8(2):28-37.

  29. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000;41(3):764-74.

  30. Son JL, Soto I, Oglesby E, et al. Glaucomatous optic nerve injury involves early astrocyte reactivity and late oligodendrocyte loss. Glia. 2010;58(7):780-9.

  31. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res. 1999;18(1):39-57.

  32. Johnson AT, Drack AV, Kwitek AE, Cannon RL, Stone EM, Alward WL. Clinical features and linkage analysis of a family with autosomal dominant juvenile glaucoma. Ophthalmology. 1993;100(4):524-9.

  33. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey. Arch Ophthalmol. 1994;112(1):69-73.

  34. Stoilova D, Child A, Trifan OC, Crick RP, Coakes RL, Sarfarazi M. Localization of a locus (GLC1B) for adult-onset primary open angle glaucoma to the 2cen-q13 region. Genomics. 1996;36(1):142-50.

  35. Hauser MA, Allingham RR, Linkroum K, et al. Distribution of WDR36 DNA sequence variants in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2006;47(6):2542-6.

  36. Demetriades AM. Gene therapy for glaucoma. Curr Opin Ophthalmol. 2011;22(2):73-7.

  37. Cartwright MJ, Grajewski AL, Friedberg ML, Anderson DR, Richards DW. Immune-related disease and normal-tension glaucoma. A case-control study. Arch Ophthalmol. 1992;110(4):500-2.

  38. Vohra R, Tsai JC, Kolko M. The role of inflammation in the pathogenesis of glaucoma. Surv Ophthalmol. 2013;58(4):311-20.

  39. Schwartz M. Neurodegeneration and neuroprotection in glaucoma: development of a therapeutic neuroprotective vaccine: the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2003;44(4):1407-11.

  40. Kipnis J, Schwartz M. Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. Trends Mol Med. 2002;8:319-23.

  41. Bakalash S, Kipnis J, Yoles E, Schwartz M. Resistance of retinal ganglion cells to an increase in intraocular pressure is immune- dependent. Invest Ophthalmol Vis Sci. 2002:43:2648-53.

  42. Kipnis J, Yoles E, Porat Z, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A. 2000 20;97(13):7446-51.

  43. Schori H, Kipnis J, Yoles E, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci USA. 2001;98:3398-403.

  44. Schwartz M. Modulating the immune system: a vaccine for glaucoma? Can J Ophthalmol. 2007;42(3):439-41.

  45. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005;120:513-22.

  46. Liton PB, Challa P, Stinnett S, Luna C, Epstein DL, Gonzalez P. Cellular senescence in the glaucomatous outflow pathway. Exp Gerontol. 2005;40(8-9):745-8.

  47. Mozaffarieh M, Grieshaber MC, Orgül S, Flammer J. The potential value of natural antioxidative treatment in glaucoma. Surv Ophthalmol. 2008; 53(5):479-505.

  48. Guo MS, Wu YY, Liang ZB. Hyaluronic acid increases MMP-2 and MMP- 9 expressions in cultured trabecular meshwork cells from patients with primary open-angle glaucoma. Mol Vis. 2012;18:1175-81.

  49. Baleriola J, García-Feijoo J, Martínez-de-la-Casa JM, Fernández-Cruz A, de la Rosa EJ, Fernández-Durango R. Apoptosis in the trabecular meshwork of glaucomatous patients. Mol Vis. 2008;14:1513-6.

  50. Yu AL, Birke K, Moriniere J, Welge-Lüssen U. TGF-{beta}2 induces senescence- associated changes in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2010;51(11):5718-23.




2020     |     www.medigraphic.com